Comparative Pharmacology
Head-to-head clinical analysis: ANGIOMAX versus EMBLAVEO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANGIOMAX versus EMBLAVEO.
ANGIOMAX vs EMBLAVEO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Direct thrombin inhibitor that reversibly binds to the active site of thrombin, blocking its interaction with substrates, thereby inhibiting fibrin formation and activation of coagulation factors V, VIII, and XIII.
EMBLAVEO is a combination of a beta-lactam antibiotic (cefepime) and a beta-lactamase inhibitor (enmetazobactam). Enmetazobactam inhibits a broad range of beta-lactamases, including ESBLs and AmpC, thereby protecting cefepime from hydrolysis and extending its spectrum of activity against beta-lactamase-producing Gram-negative bacteria.
1 mg/kg intravenous bolus followed by 0.1 mg/kg/hour continuous intravenous infusion for duration of procedure; alternatively, 0.75 mg/kg intravenous bolus followed by 1.75 mg/kg/hour continuous intravenous infusion for up to 4 hours during percutaneous coronary intervention.
EMBLAVEO (imipenem/cilastatin/relebactam) is administered intravenously. The recommended adult dose is 1.25 g (imipenem 500 mg, cilastatin 500 mg, relebactam 250 mg) every 6 hours infused over 30 minutes.
None Documented
None Documented
Terminal elimination half-life: 25-30 minutes in patients with normal renal function; increased to 2-3 hours in dialysis-dependent patients
Terminal elimination half-life is 11–12 hours in healthy adults; prolonged to 20–30 hours in severe renal impairment (CrCl <30 mL/min).
Renal: ~90% unchanged; biliary/fecal: negligible (<1%)
Renal excretion of unchanged drug accounts for approximately 30% of the dose; biliary/fecal elimination accounts for about 70% (60% fecal as parent drug and metabolites, 10% biliary).
Category C
Category C
Anticoagulant
Anticoagulant